Conserved C143 forms a branched intermediate in Hedgehog autoprocessing: A cancer drug discovery target against Hedgehog signaling
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2415144122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Shannon Faris und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, NY 12180. Hauptthemen laut MEDLINE: Hedgehog Proteins, Signal Transduction, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, HHS | National Institutes of Health (NIH), NCI NIH HHS.
Abstract (Originalsprache)
Hedgehog (Hh) signaling plays fundamental roles in embryonic development while its abnormal activation in adults is associated with cancer. Hh targeting drugs have gained FDA approval but resistance emerged quickly, underlining the need for novel types of Hh inhibitors. Hh signaling is initiated by the Hh ligand, generated from the autoprocessing of Hh precursor. However, the catalytic role of a highly conserved Hedgehog residue C143 is still poorly understood. Here, we confirmed that C143 is required for Hh autoprocessing in mammalian cells. NMR titration showed that C143 has an extremely low pK a of 4.5, befitting a highly reactive catalytic residue. We further established that Hh autoprocessing involves a branched intermediate (BI) with two N-termini, formed as a thioester on the C143 sidechain. BI migrates slower than the linear Hh precursor on SDS-PAGE and disappears with DTT treatment. With trypsin digestion and LC–MS/MS, we detected the N-terminal fragment from BI, which is absent from the linear Hh precursor. Therefore, C143 mediates the formation of a BI thioester in Hh autoprocessing, with a catalytic role equivalent to C + 1 in intein splicing. These findings bring us closer to a full mechanistic understanding of Hh autoprocessing while unifying the first two catalytic steps of Hh autoprocessing with intein splicing, its likely evolutionary predecessor. C143 can also serve as a target for covalent drugs for inhibiting Hh signaling in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, NY 12180.
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180.
- Department of Chemistry, Binghamton University, Binghamton, NY 13902.
- Department of Chemistry, State University of New York-Environmental Science and Forestry, Syracuse, NY 13210.
- Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE 68198.
ORCID-Profile: Shannon Faris, Ke Xia, Andrew G Wagner, Zihan Xu, Nathan Smith, Brian Callahan, Jian Xie, Chunyu Wang
Förderung
- NIGMS NIH HHS
- HHS | National Institutes of Health (NIH)
- NCI NIH HHS
- NIA NIH HHS
- NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
Zitieren
APA
Faris, S., Xia, K., Wagner, A. G., Xu, Z., Smith, N., Giner, J. L., Callahan, B., Xie, J., & Wang, C. (2025). Conserved C143 forms a branched intermediate in Hedgehog autoprocessing: A cancer drug discovery target against Hedgehog signaling. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2415144122
Vancouver
Faris S, Xia K, Wagner AG, Xu Z, Smith N, Giner JL, et al. Conserved C143 forms a branched intermediate in Hedgehog autoprocessing: A cancer drug discovery target against Hedgehog signaling. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2415144122
BibTeX
@article{Faris2025,
author = {Faris, Shannon and Xia, Ke and Wagner, Andrew G and Xu, Zihan and Smith, Nathan and Giner, José-Luis and Callahan, Brian and Xie, Jian and Wang, Chunyu},
title = {Conserved C143 forms a branched intermediate in Hedgehog autoprocessing: A cancer drug discovery target against Hedgehog signaling},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2415144122}
}
EUVIMED